Hjem › Lungekreft › Kentucky
Kliniske studier for Lungekreft i Kentucky
26 studier for Lungekreft søker deltakere på steder i Kentucky.
Byer i Kentucky
Offisiell studietekst (engelsk)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Baptist Health Corbin, Corbin
- Baptist Health Hardin, Elizabethtown
- Baptist Health Lexington, Lexington
- og 3 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT04267848Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
- University of Kentucky Chandler Medical Center ( Site 0019), Lexington
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06780098Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- CommonSpirit Saint Joseph Hospital - Bardstown, Bardstown
- Commonwealth Cancer Center-Corbin, Corbin
- Saint Elizabeth Healthcare Edgewood, Edgewood
- og 5 flere
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 40 til 75 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05334069Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- University of Kentucky/Markey Cancer Center, Lexington
- The James Graham Brown Cancer Center at University of Louisville, Louisville
- UofL Health Medical Center Northeast, Louisville
RekruttererFase 3
Alder 70 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06096844A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Saint Elizabeth Medical Center Edgewood-Cancer Care Center ( Site 0061), Edgewood
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06312137A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Baptist Health Lexington, Lexington
- University of Kentucky Chandler Medical Center, Lexington
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 23. sep. 2026 · NCT07063745Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- Baptist Health Hardin, Elizabethtown
- Baptist Health Lexington, Lexington
- University of Kentucky Chandler Medical Center (UKCMC) - Markey Cancer Center (Lucille P. Markey Cancer Center), Lexington
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT06712316Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
- University of Kentucky/Markey Cancer Center, Lexington
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 17. sep. 2026 · NCT06287775A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- CHI Saint Joseph Cancer Center - East, Lexington
- University of Kentucky Chandler Medical Center, Lexington
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 8. sep. 2026 · NCT06119581Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- Baptist Health Hardin Cancer Center, Elizabethtown
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 1. sep. 2026 · NCT06712355A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
- University of Kentucky ( Site 0019), Lexington
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 18. aug. 2026 · NCT06731907Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
- Xencor Investigative Site, Louisville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 3. aug. 2026 · NCT05433142Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Norton Cancer Institute, Louisville
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 29. jul. 2026 · NCT04198766Safety and Efficacy of OBX-115 in Advanced Solid Tumors
- James Graham Brown Cancer Center (Melanoma/NSCLC), Louisville
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 16. jul. 2026 · NCT06060613EXoPERT EMERALD Clinical Study
- Lexington VA Healthcare System, Lexington
- KCTL, Louisville
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 45 og eldre · Alle kjønn · Oppdatert 1. jul. 2026 · NCT07186296Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
- University of Louisville, Louisville
RekruttererFase 2
Alder 18 til 70 · Alle kjønn · Oppdatert 26. jun. 2026 · NCT04614103A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
- University of Louisville, Louisville
RekruttererFase 1/2
Alder 18 til 70 · Alle kjønn · Oppdatert 11. jun. 2026 · NCT05361174Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- University of Kentucky/Markey Cancer Center, Lexington
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 3. jun. 2026 · NCT05642572Pathways, a Hope Intervention to Support Personal Goal Pursuit, Mental Health, and Quality of Life During Advanced Lung Cancer Treatment
- University of Kentucky, Lexington
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 8. mai 2026 · NCT06047301A Study of ZW251 in Participants With Advanced Solid Tumors
- Norton Cancer Institute, Louisville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 7. mai 2026 · NCT07164313Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- University of Kentucky/Markey Cancer Center, Lexington
RekruttererFase 2
18 Minutes · Alle kjønn · Oppdatert 5. mai 2026 · NCT06031688Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- University of Kentucky/Markey Cancer Center, Lexington
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 5. mai 2026 · NCT06616584Precision Lung Cancer Survivorship Care Intervention
- Markey Cancer Center, Lexington
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 23. feb. 2026 · NCT05857995A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- University of Kentucky Markey Cancer Center, Lexington
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 13. feb. 2026 · NCT06778863cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Baptist Corbin, Corbin
- Baptist Hardin, Elizabethtown
- Baptist Lexington, Lexington
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 40 og eldre · Alle kjønn · Oppdatert 20. jan. 2026 · NCT05366881Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier
- Lexington VA Health Care System, Lexington
- Robley Rex VA Medical Center, Louisville
RekruttererObservasjonsstudie
Alder 29 til 85 · Alle kjønn · Oppdatert 13. nov. 2024 · NCT06426628Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.